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The prevalence of Helicobacter pylori infection was
studied in 138 patients with dyspepsia in a hospital in
Nakuru, Kenya, and in 138 asymptomatic sex- and age-
matched controls from the same population. Anti–H. pylori
immunoglobulin (Ig) G was more prevalent in dyspeptic
than asymptomatic persons (71% vs. 51%), particularly
those <30 years old (71% vs. 38%). H. pylori seropositivity
was associated with dyspepsia after adjusting for age, sex,
and residence (urban or rural). Among adults, the associa-
tion between H. pylori infection and dyspepsia remained
after adjusting for the above factors and for educational
attainment, family size, and manual occupation. H. pylori
infection in asymptomatic residents of Nakuru, Kenya, was
more prevalent in older persons, with a rate of 68%, than in
those 31–40 years of age. However, young persons with
dyspepsia had an unexpectedly high prevalence of H.
pylori infection. H. pylori test-and-treat strategy should be
considered in Kenyan patients with dyspepsia, particularly
in persons <30 years of age. 
D
yspepsia is a complex set of symptoms, rather than an
indication of a specific disease, and defies simple cat-
egorization. Many causes of dyspepsia exist, including
Helicobacter pylori. H. pylori may also produce different
symptoms in different people. Moreover, what is known
about variations in host susceptibility and H. pylori viru-
lence has not been correlated with specific symptoms (1).
Many patients with upper gastrointestinal symptoms
who seek health care do not have follow up treatment. In
60% of the investigated patients, results of tests to rule out
peptic ulcer disease, gastro-esophageal reflux disease, and
gastric cancer are normal, and the diagnosis is functional
dyspepsia (2). The benefit of treatment to eradicate H. pylori
in functional dyspepsia remains controversial (3,4). To man-
age uninvestigated dyspepsia in developed countries, some
authors recommend screening patients <50 years of age
without severe symptoms with a noninvasive test for H.
pylori, and then treat those with positive results with H.
pylori–eradicating drugs (5). However, in Africa, a dispari-
ty exists between the high prevalence of H. pylori infection
(>90% in many areas) (6) and the occurrence of clinically
important disease (“the African enigma”). This finding has
led researchers to postulate that H. pylori does not play a
major role in the etiologic findings of upper gastrointestinal
system pathology apart, from gastritis (7,8). Thus, a nonin-
vasive H. pylori test-and-treat strategy in a primary care set-
ting in an economically depressed area, such as Africa,
should be based on data that show an association between
dyspepsia and H. pylori infection. The aim of our case-con-
trol study was to investigate the association between H.
pylori infection and dyspepsia in Nakuru, Kenya.
Materials and Methods 
Selection of Patients
Patients who arrived at the outpatient Gastroenterology
Clinic of the Rift Valley Hospital in Nakuru, Kenya, with
uninvestigated symptoms of dyspepsia for atleast the pre-
vious 3 months were included in the study. Inclusion crite-
ria were 1) presence of at least two of the following symp-
toms; upper abdominal pain or discomfort, bloating, nau-
sea, vomiting, or early satiety; 2) persistent or recurrent
symptoms occurring at least three times per week during
>6 months in the year or years preceding the study; 3)
absence of nocturnal or postprandial symptoms of gastroe-
sophageal reflux; 4) no previous abdominal surgeryexcept
for uncomplicated appendectomy, cholecystectomy, or
herniarepair.
For every dyspeptic patient, a sex- and age-matched
control was recruited from a convenience sample of
asymptomatic persons from the local community of
Nakuru by public advertisement. Dyspepsia in the control
group was excluded by clinical interview and a structured
screening questionnaire. 
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All participants (patients and asymptomatic partici-
pants) were interviewed by one of the authors (S.O.), a
local Kenyan physician, to assess symptoms. A bowel dis-
ease questionnaireformulated on the basis of a previously
validated instrument (the Bowel Disease Questionnaire)
was used, modified, and shortened to accommodate local
Kenyan needs (9). 
Demographic and Socioeconomic Status 
Participants were questioned about demographic data
and current and childhood socioeconomic status. Age was
coded into five categories (0–20, 21–30, 31–40, 41–50,
and >50 years of age); among adults >21 years of age,
occupation was classified as manual versus nonmanual
(clerical, professional, homemaker); educational attain-
ment as less than or at least eighth grade; number of sib-
lings as less than or at least 7; residence as urban or rural;
tobacco use as ever or never smoked cigarettes; alcohol
use as less than or at least 1 L of beer or 0.5 L of wine
(average 50 g ethanol) per week.
Determination of H. pylori status 
Whole blood was obtained from all participants. Anti-
H. pylori immunoglobulin (Ig) G was determined with the
Helisal Rapid Blood Test kit (Cortecs Diagnostics, UK).
This test achieved 89% sensitivity and 91% specificity ver-
sus histologic examination and urease testing in Australian
adults (10). 
Kits were stored at 4°C and equilibrated to room tem-
perature beforeuse. The tests were performed according to
the manufacturer’s instructions. All results were read by
one of the authors (S.O.). Our laboratory recently evaluat-
ed the Helisal test in 20 Israeli adults (20–70 years of age,
median 42 years of age), and demonstrated the test to be
100% sensitive and 90% specific (11). 
Statistical Analysis
Bivariate analyses were performed by using the Fisher
exact test for categorical variables and the Student t test or
Kruskal-Wallis two-sample test for integer and continuous
variables. Multivariate analyses were performed by apply-
ing backwards-elimination logistic regression to all demo-
graphic and socioeconomic variables evaluated in the
bivariate analyses; parsimonious models were developed,
which included only age and those variables associated
with a mutually adjusted p value of <0.10. Only partici-
pants >21 years of age were included in the models inves-
tigating the role of education, occupation, and family size
on the H. pylori–dyspepsia relationship. All p values were
two-tailed.
Results 
Seropositivity for H. pylori was found in 98 (71%) of
138 symptomatic patients and 70 (51%) of 138 asympto-
matic participants (odds ratio [OR], 2.4; 95% confidence
interval [CI], 1.4 to 4.0; p<0.001). In the asymptomatic
participants, the prevalence of H. pylori infection
increased with age, from 18% in the 0- to 10-year age
group to 48% in the 11- to 20-year age group, peaking
(68%) in the 31- to 40-year age group. In the dyspeptic
patients, the prevalence of H. pylori infection was 60% to
73% in all age groups (Table 1). Among persons <21 years
old, H. pylori infection was more prevalent in those with
symptoms than those without (17 [71%] of 24 vs.12 [38%]
of 31; OR, 4.1; 95% CI, 1.1 to 14.9; p=0.02). Similarly, H.
pylori seropositivity showed a significant association with
dyspepsia among persons 21–30 years of age (35 [73%] of
48 vs. 36 [48%] of 74; OR, 2.6; 95% CI 1.2 to 6.7;
p=0.01), but not among persons >30 years of age (46
[70%] of 66 vs. 20 [63%] of 32; OR, 1.4; 95% CI, 0.4 to
2.8; p=0.8).
On bivariate analysis, infection with H. pylori, older
age, female sex, working as a manual laborer (>21 years of
age), less education, and larger family size (>7 siblings)
were associated with dyspepsia in adults (Table 2). H.
pylori infection was associated with dyspepsia after adjust-
ing for age, sex, and urban residence (OR, 2.0; CI, 1.1 to
3.3; p=0.02), and among adults, after adjusting for these
factors and for education, family size, and occupation (OR,
2.4; 95% CI, 1.1 to 4.9; p=0.02) (Table 3).
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Table 1. Risk (prevalence odds ratios) of upper gastrointestinal symptoms associated with Helicobacter pylori infection by age, among 
276 residents of Nakuru, Kenya 
Age (y)  Cases
a  (N=138) (%)  Controls
b (N=138) (%)  OR (95% CI)
c  p value 
0–20  17/24 (71)  12/32 (38)  4.1 (1.1 to 14.9)  0.02 
21–30  35/48 (73)  36/74 (48)  2.6 (1.2 to 6.7)  0.01 
31–40  27/38 (71)  15/22 (68)  1.2 (0.3 to 4.1)  1.0 
41–50  13/18 (72)  3/6 (50)  2.6 (0.5 to 26.3)  0.4 
>50  6/10 (60)  2/4 (50)  1.3 (0.1 to 20.2)  1.0 
0–30  52/72 (72)  48/108 (44)  3.3 (1.6 to 6.5)  <0.001 
>30  46/66 (70)  20/32 (63)  1.0 (0.4 to 2.8)  0.8 
aPersons with upper gastrointestinal symptoms. 
bPersons without upper gastrointestinal symptoms. 
cOR, odds ratio; CI, confidence interval. Discussion
This  H. pylori serologic study in residents of the
Nakuru District of Kenya found the expected relationship
between H. pylori prevalence and age among asympto-
matic participants. However, among persons with dyspep-
sia, the prevalence was consistently high for all ages,
which yielded an unequivocal association between H.
pylori infection and dyspepsia among persons <30 years of
age.
Other studies of Africans with dyspepsia have yielded a
mean prevalence of 65% (range 60% to 71%), which is
consistent with our results (12,13). Our recruitment strate-
gy was very similar to the strategy of a study conducted in
Cape Town, South Africa (13). In that 1993 study, H.
pylori prevalence among a subset of Africans of non-
Caucasian descent with nonulcer dyspepsia attending a
gastroenterology clinic was 71%, the same as in our study.
However, since the South African study did not include
healthy controls, no generalizations can be made about the
association between H. pylori and dyspepsia in different
part of the continent. Recently, healthy Nigerian adults and
dyspeptic patients were found to have similar prevalence
of H. pylori infection (80% vs. 88%), but the sample size
(50 persons) may have been too small to detect the moder-
ate effects found in our and other’s studies, particularly in
the subgroup of persons <30 years of age (14). 
The role of H. pylori in dyspepsia is poorly understood
(15,16). Dyspeptic symptoms are common in sub-Saharan
Africa (17); in some regions, they may account for up to
10% of hospital admissions (18). Because healthcare
resources in Kenya are limited, physicians direct diagnos-
tic tests for patients in whom a definitive diagnosis is
important for treatment (e.g., those with peptic ulcer or
gastric cancer). Since a large fraction of the dyspepsia in
younger Africans is attributable to H. pylori, and since dys-
pepsia in this age group is likely to represent a benign
process, a test-and-treat strategy may be appropriate in this
age group. This approach involves H. pylori testing of
uninvestigateddyspepticpatients without severe symptoms
or signs suggestiveof underlying malignancy (unexplained
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Table 2. Risk factors for upper gastrointestinal symptoms among 276 residents of Nakuru, Kenya 
Risk factor  Cases
a N=138 (%)  Controls
b N=138 (%)  OR (95% CI)
c  p value 
Helicobacter pylori infection  98/138 (71)  70/138 (51)  2.4 (1.5 to 3.9)  <0.001 
Less education
d,e  42/114 (37)  16/106 (15)  3.3 (1.71 to 6.27)  <0.001 
>7 siblings
d  77/114 (68)  44/105 (42)  2.9 (1.7 to 5.0)  <0.001 
Manual laborer
d,f  32/91 (35)  9/73 (12)  3.9 (1.7 to 8.6)  <0.001 
Female gender  81/138 (59)  56/138 (41)  2.1 (1.3 to 3.4)  0.003 
Alcohol use
d  8/113 (7)  21/104 (20)  0.3 (0.1 to 0.7)  0.005 
Ever smoked
d  6/115 (7)  3/105 (3)  1.9 (0.5 to 7.0)  0.4 
Urban residence
g  86/138 (62)  80/138 (58)  1.2 (0.7 to 1.9)  0.5 
Age, median (range)  30 y (1–62)  23 y (2–74)    0.001 
aPersons with upper gastrointestinal symptoms. 
bPersons without upper gastrointestinal symptoms. 
cOR, odds ratio; CI, confidence interval. 
dAdults >21 years of age.  
eUp to 8th grade. 
fManual laborers versus persons in clerical or professional fields or housewives. 
gCity or town versus rural. 
Table 3. Risk factors for upper gastrointestinal symptoms among 276 residents of Nakuru, Kenya 
  All ages  Adults >21 y 
Risk factor  OR (95% CI)
a  p value  OR (95% CI)  p value 
Helicobacter pylori infection  2.2 (1.3 to 3.8)  0.003  2.2 (1.1 to 4.8)  0.03 






21–30  0.7 (0.4 to 1.4)  0.3  1.0
 b  —
c 
31–40  2.1 (1.0 to 4.7)  0.06  1.5 (0.7 to 3.4)  0.3 
41–50  (1.2 to 11.4)  0.02  3.5 (1.1 to 11.1)  0.03 
>50  (0.9 to 13.2)  0.06  2.0  (1.4 to 9.0)  0.4 
Female gender  2.2 (1.3 to 3.7)  0.003  —
d  — 
>7 siblings  —
c  —  3.2 (1.5 to 7.0)  0.003 
Manual laborer  —
c  —  3.5 (1.4 to 9.3)  0.003 
Ever smoked  —
c    19.4 (1.5 to 256.7)  0.02 
Alcohol use  —
c    0.3 (0.1 to 1.0)  0.05 
aOR, odds ration; CI, confidence interval; —, not applicable. 
bReference group. 
cVariable not included in all-ages model. 
dRemoved by backwards-elimination logistic regression. recent weight loss, dysphagia, hematemesis or melena,
anemia, previous gastric surgery, and palpable mass).
Those with positive results would undergo H. pylori erad-
ication therapy before endoscopy is considered. Those
testing negative would undergo endoscopy only if dietary
and behavioral maneuvers do not ameliorate the com-
plaints. 
Our study has several limitations. We did not investi-
gate the underlying causes of dyspepsia, so we may have
included an unknown number of participants with peptic
ulcer disease or other organic pathology. Additional limita-
tions include the use of convenience (self-selected) con-
trols as a proxy for population controls and the use of
prevalence ORs (to make the crude and adjusted risks
commensurate) instead of risk ratios. These factors may
have led us to overestimate the association between H.
pylori and dyspepsia. On the other hand, the use of a test
with imperfect sensitivity and specificity may have led us
to underestimate this association. 
In a recent, randomized, placebo-controlled trial in a
developed country, eradication therapy proved successful
in a subset of patients with nonulcer dyspepsia (19).
However, these findings were not confirmed in another
trial of similar design (20). This disparity suggests either
that  the relationship between H. pylori and nonulcer dys-
pepsia is weak or that dyspepsia is a heterogeneous disor-
der. Thus, the effectiveness of a test-and-treat strategy in
the developing world may vary by the population studied
or by biological and cultural differences in the definition of
dyspepsia.
This study demonstrates that in Nakuru, Kenya, H.
pylori infection is associated with dyspepsia, particularly
in persons <30 years of age. Since solid evidence exists
that H. pylori eradication prevents the development (21)
and recurrence (22) of gastric carcinoma and promotes
regression of B-cell lymphoma of the mucosa-associated
lymphoid tissue (MALT) tissue of the stomach (23), the
proposed test-and-treat strategy may be an efficient use of
health resources in Kenya and perhaps other African coun-
tries.
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